
Global GLP-1 Targeted Peptide Weight Loss Drugs Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global GLP-1 Targeted Peptide Weight Loss Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for GLP-1 Targeted Peptide Weight Loss Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for GLP-1 Targeted Peptide Weight Loss Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the GLP-1 Targeted Peptide Weight Loss Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for GLP-1 Targeted Peptide Weight Loss Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the GLP-1 Targeted Peptide Weight Loss Drugs market include Chugai Pharmaceutical, Benemae Pharmaceutical, Qilu Pharmaceutical, Jiuyuan Gene Engineering, Huadong Medicine, Zealand Pharma, The General Hospital Corp, Sanofi-Aventis and QuiaPEG Pharmaceuticals Ab, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for GLP-1 Targeted Peptide Weight Loss Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of GLP-1 Targeted Peptide Weight Loss Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for GLP-1 Targeted Peptide Weight Loss Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the GLP-1 Targeted Peptide Weight Loss Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global GLP-1 Targeted Peptide Weight Loss Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for GLP-1 Targeted Peptide Weight Loss Drugs sales, projected growth trends, production technology, application and end-user industry.
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Company
Chugai Pharmaceutical
Benemae Pharmaceutical
Qilu Pharmaceutical
Jiuyuan Gene Engineering
Huadong Medicine
Zealand Pharma
The General Hospital Corp
Sanofi-Aventis
QuiaPEG Pharmaceuticals Ab
Orbis Biosciences
Novo Nordisk
Nano Precision Medical
Nanexa AB
Lexaria Bioscience
iX Biopharma
Intarcia Therapeutics
HIKMA PHARMS
Eli Lilly
Baxter Pharmaceutical
Astra Zeneca
Amylin Pharmaceuticals
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Type
Oral
Injection
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Application
Hospital
Clinic
Others
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global GLP-1 Targeted Peptide Weight Loss Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions GLP-1 Targeted Peptide Weight Loss Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify GLP-1 Targeted Peptide Weight Loss Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze GLP-1 Targeted Peptide Weight Loss Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Targeted Peptide Weight Loss Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Targeted Peptide Weight Loss Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Targeted Peptide Weight Loss Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the GLP-1 Targeted Peptide Weight Loss Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GLP-1 Targeted Peptide Weight Loss Drugs industry.
Chapter 3: Detailed analysis of GLP-1 Targeted Peptide Weight Loss Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of GLP-1 Targeted Peptide Weight Loss Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of GLP-1 Targeted Peptide Weight Loss Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global GLP-1 Targeted Peptide Weight Loss Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for GLP-1 Targeted Peptide Weight Loss Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for GLP-1 Targeted Peptide Weight Loss Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the GLP-1 Targeted Peptide Weight Loss Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for GLP-1 Targeted Peptide Weight Loss Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the GLP-1 Targeted Peptide Weight Loss Drugs market include Chugai Pharmaceutical, Benemae Pharmaceutical, Qilu Pharmaceutical, Jiuyuan Gene Engineering, Huadong Medicine, Zealand Pharma, The General Hospital Corp, Sanofi-Aventis and QuiaPEG Pharmaceuticals Ab, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for GLP-1 Targeted Peptide Weight Loss Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of GLP-1 Targeted Peptide Weight Loss Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for GLP-1 Targeted Peptide Weight Loss Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the GLP-1 Targeted Peptide Weight Loss Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global GLP-1 Targeted Peptide Weight Loss Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for GLP-1 Targeted Peptide Weight Loss Drugs sales, projected growth trends, production technology, application and end-user industry.
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Company
Chugai Pharmaceutical
Benemae Pharmaceutical
Qilu Pharmaceutical
Jiuyuan Gene Engineering
Huadong Medicine
Zealand Pharma
The General Hospital Corp
Sanofi-Aventis
QuiaPEG Pharmaceuticals Ab
Orbis Biosciences
Novo Nordisk
Nano Precision Medical
Nanexa AB
Lexaria Bioscience
iX Biopharma
Intarcia Therapeutics
HIKMA PHARMS
Eli Lilly
Baxter Pharmaceutical
Astra Zeneca
Amylin Pharmaceuticals
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Type
Oral
Injection
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Application
Hospital
Clinic
Others
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global GLP-1 Targeted Peptide Weight Loss Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions GLP-1 Targeted Peptide Weight Loss Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify GLP-1 Targeted Peptide Weight Loss Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze GLP-1 Targeted Peptide Weight Loss Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Targeted Peptide Weight Loss Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Targeted Peptide Weight Loss Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Targeted Peptide Weight Loss Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the GLP-1 Targeted Peptide Weight Loss Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GLP-1 Targeted Peptide Weight Loss Drugs industry.
Chapter 3: Detailed analysis of GLP-1 Targeted Peptide Weight Loss Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of GLP-1 Targeted Peptide Weight Loss Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of GLP-1 Targeted Peptide Weight Loss Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
219 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2020-2031)
- 1.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume (2020-2031)
- 1.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 GLP-1 Targeted Peptide Weight Loss Drugs Market Dynamics
- 2.1 GLP-1 Targeted Peptide Weight Loss Drugs Industry Trends
- 2.2 GLP-1 Targeted Peptide Weight Loss Drugs Industry Drivers
- 2.3 GLP-1 Targeted Peptide Weight Loss Drugs Industry Opportunities and Challenges
- 2.4 GLP-1 Targeted Peptide Weight Loss Drugs Industry Restraints
- 3 GLP-1 Targeted Peptide Weight Loss Drugs Market by Company
- 3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Revenue Ranking in 2024
- 3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Company (2020-2025)
- 3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Company (2020-2025)
- 3.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Average Price by Company (2020-2025)
- 3.5 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Ranking (2023-2025)
- 3.6 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Manufacturing Base and Headquarters
- 3.7 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Product Type and Application
- 3.8 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 GLP-1 Targeted Peptide Weight Loss Drugs Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 GLP-1 Targeted Peptide Weight Loss Drugs Market by Type
- 4.1 GLP-1 Targeted Peptide Weight Loss Drugs Type Introduction
- 4.1.1 Oral
- 4.1.2 Injection
- 4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Type
- 4.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Type (2020-2031)
- 4.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share by Type (2020-2031)
- 4.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Type
- 4.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Type (2020-2031)
- 4.3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type (2020-2031)
- 5 GLP-1 Targeted Peptide Weight Loss Drugs Market by Application
- 5.1 GLP-1 Targeted Peptide Weight Loss Drugs Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Application
- 5.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Application (2020-2031)
- 5.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share by Application (2020-2031)
- 5.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Application
- 5.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Application (2020-2031)
- 5.3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application (2020-2031)
- 6 GLP-1 Targeted Peptide Weight Loss Drugs Regional Sales and Value Analysis
- 6.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2020-2031)
- 6.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2020-2025
- 6.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2026-2031)
- 6.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Region (2020-2031)
- 6.4.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Region: 2020-2025
- 6.4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Region (2026-2031)
- 6.5 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2020-2031)
- 6.6.2 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2020-2031)
- 6.7.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2020-2031)
- 6.8.2 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2020-2031)
- 6.9.2 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2020-2031)
- 6.10.2 Middle East & Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country, 2024 VS 2031
- 7 GLP-1 Targeted Peptide Weight Loss Drugs Country-level Sales and Value Analysis
- 7.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2031)
- 7.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2025)
- 7.3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2026-2031)
- 7.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Country (2020-2031)
- 7.4.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Country (2020-2025)
- 7.4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.5.2 USA GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.9.2 France GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.16.2 China GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.19.2 India GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Chugai Pharmaceutical
- 8.1.1 Chugai Pharmaceutical Comapny Information
- 8.1.2 Chugai Pharmaceutical Business Overview
- 8.1.3 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.1.5 Chugai Pharmaceutical Recent Developments
- 8.2 Benemae Pharmaceutical
- 8.2.1 Benemae Pharmaceutical Comapny Information
- 8.2.2 Benemae Pharmaceutical Business Overview
- 8.2.3 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.2.5 Benemae Pharmaceutical Recent Developments
- 8.3 Qilu Pharmaceutical
- 8.3.1 Qilu Pharmaceutical Comapny Information
- 8.3.2 Qilu Pharmaceutical Business Overview
- 8.3.3 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.3.5 Qilu Pharmaceutical Recent Developments
- 8.4 Jiuyuan Gene Engineering
- 8.4.1 Jiuyuan Gene Engineering Comapny Information
- 8.4.2 Jiuyuan Gene Engineering Business Overview
- 8.4.3 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.4.5 Jiuyuan Gene Engineering Recent Developments
- 8.5 Huadong Medicine
- 8.5.1 Huadong Medicine Comapny Information
- 8.5.2 Huadong Medicine Business Overview
- 8.5.3 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.5.5 Huadong Medicine Recent Developments
- 8.6 Zealand Pharma
- 8.6.1 Zealand Pharma Comapny Information
- 8.6.2 Zealand Pharma Business Overview
- 8.6.3 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.6.5 Zealand Pharma Recent Developments
- 8.7 The General Hospital Corp
- 8.7.1 The General Hospital Corp Comapny Information
- 8.7.2 The General Hospital Corp Business Overview
- 8.7.3 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.7.4 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.7.5 The General Hospital Corp Recent Developments
- 8.8 Sanofi-Aventis
- 8.8.1 Sanofi-Aventis Comapny Information
- 8.8.2 Sanofi-Aventis Business Overview
- 8.8.3 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.8.5 Sanofi-Aventis Recent Developments
- 8.9 QuiaPEG Pharmaceuticals Ab
- 8.9.1 QuiaPEG Pharmaceuticals Ab Comapny Information
- 8.9.2 QuiaPEG Pharmaceuticals Ab Business Overview
- 8.9.3 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.9.4 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.9.5 QuiaPEG Pharmaceuticals Ab Recent Developments
- 8.10 Orbis Biosciences
- 8.10.1 Orbis Biosciences Comapny Information
- 8.10.2 Orbis Biosciences Business Overview
- 8.10.3 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.10.5 Orbis Biosciences Recent Developments
- 8.11 Novo Nordisk
- 8.11.1 Novo Nordisk Comapny Information
- 8.11.2 Novo Nordisk Business Overview
- 8.11.3 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.11.5 Novo Nordisk Recent Developments
- 8.12 Nano Precision Medical
- 8.12.1 Nano Precision Medical Comapny Information
- 8.12.2 Nano Precision Medical Business Overview
- 8.12.3 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.12.5 Nano Precision Medical Recent Developments
- 8.13 Nanexa AB
- 8.13.1 Nanexa AB Comapny Information
- 8.13.2 Nanexa AB Business Overview
- 8.13.3 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.13.5 Nanexa AB Recent Developments
- 8.14 Lexaria Bioscience
- 8.14.1 Lexaria Bioscience Comapny Information
- 8.14.2 Lexaria Bioscience Business Overview
- 8.14.3 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.14.4 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.14.5 Lexaria Bioscience Recent Developments
- 8.15 iX Biopharma
- 8.15.1 iX Biopharma Comapny Information
- 8.15.2 iX Biopharma Business Overview
- 8.15.3 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.15.4 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.15.5 iX Biopharma Recent Developments
- 8.16 Intarcia Therapeutics
- 8.16.1 Intarcia Therapeutics Comapny Information
- 8.16.2 Intarcia Therapeutics Business Overview
- 8.16.3 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.16.4 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.16.5 Intarcia Therapeutics Recent Developments
- 8.17 HIKMA PHARMS
- 8.17.1 HIKMA PHARMS Comapny Information
- 8.17.2 HIKMA PHARMS Business Overview
- 8.17.3 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.17.4 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.17.5 HIKMA PHARMS Recent Developments
- 8.18 Eli Lilly
- 8.18.1 Eli Lilly Comapny Information
- 8.18.2 Eli Lilly Business Overview
- 8.18.3 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.18.4 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.18.5 Eli Lilly Recent Developments
- 8.19 Baxter Pharmaceutical
- 8.19.1 Baxter Pharmaceutical Comapny Information
- 8.19.2 Baxter Pharmaceutical Business Overview
- 8.19.3 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.19.4 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.19.5 Baxter Pharmaceutical Recent Developments
- 8.20 Astra Zeneca
- 8.20.1 Astra Zeneca Comapny Information
- 8.20.2 Astra Zeneca Business Overview
- 8.20.3 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.20.4 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.20.5 Astra Zeneca Recent Developments
- 8.21 Amylin Pharmaceuticals
- 8.21.1 Amylin Pharmaceuticals Comapny Information
- 8.21.2 Amylin Pharmaceuticals Business Overview
- 8.21.3 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2020-2025)
- 8.21.4 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 8.21.5 Amylin Pharmaceuticals Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 GLP-1 Targeted Peptide Weight Loss Drugs Value Chain Analysis
- 9.1.1 GLP-1 Targeted Peptide Weight Loss Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 GLP-1 Targeted Peptide Weight Loss Drugs Sales Mode & Process
- 9.2 GLP-1 Targeted Peptide Weight Loss Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 GLP-1 Targeted Peptide Weight Loss Drugs Distributors
- 9.2.3 GLP-1 Targeted Peptide Weight Loss Drugs Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.